Bloodstream infections in ICU with increased resistance: Epidemiology and outcomes

Minerva Anestesiologica

Volumn 81, Issue 4, 2015, Pages 405-418

  Dimopoulos, G ^a   Koulenti, D ^a,b   Tabah, A ^b,c,d   Poulakou, G ^a   Vesin, A ^e,f   Arvaniti, K ^g   Lathyris, D ^h   Matthaiou, D K ^a   Armaganidis, A ^a   Timsit, J F ^d,e,f  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIV GRENOBLE ALPES   (France)

^f OUTCOMEREA Organization   (France)

^g Department of Pathology   (Greece)

^h Gennimatas General Hospital   (Greece)

Author keywords

Bacteremia; Cross infection; Drug resistance, multiple; Outcomes

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CASPOFUNGIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; DAPTOMYCIN; FLUCONAZOLE; GENTAMICIN; HYPERTENSIVE FACTOR; IMIPENEM; INOTROPIC AGENT; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDES INFECTION; BLOODSTREAM INFECTION; CANDIDIASIS; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEUS INFECTION; PSEUDOMONAS INFECTION; RENAL REPLACEMENT THERAPY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; STAPHYLOCOCCUS INFECTION; AGED; CRITICAL ILLNESS; CROSS INFECTION; GREECE; HEMATOLOGIC DISEASES; HOSPITAL MORTALITY; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; FEMALE; GREECE; HEMATOLOGIC DISEASES; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84930009039     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598-601.
2. Garrouste-Orgeas M, Timsit JF, Tafflet M, Misset B, Zahar J-R, Soufir L et al. OUTCOMEREA Study Group. Excess risk of death from intensive care unit- acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 2006;42:1118-26.
3. Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD et al. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9.
4. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. Severe bloodstream infections: a population-based assessment. Crit Care Med 2004;32:992-7.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
6. Daikos GL, Vryonis E, Psichogiou M, Tzouvelekis LS, Liatis S, Petrikkos P et al. Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallobeta-lactamase. J Antimicrob Chemother 2010;65:784-8.
7. European Center for Disease Prevention and Control [Homepage]. [cited 2015 March 13]. Available from: http://ecdc.europa.eu/en/activities/surveillance/EARSNet/database/Pages/table-reports.aspx
8. WHONET [Homepage]. [cited 2015 March 13]. Available from: http://www.whonet.org/DNN/
9. Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F et al Canadian Antimicrobial Resistance Alliance (CARA). Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008;52:1430-7.
10. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136:1237-48.
11. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115:529-35.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987;40:373-83.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical Care Medicine 1985;13:818-29.
14. Le-Gall JR, Lemeshow S, Saulnier F. A new simplified physiology score (SAPS II) based on a European/North American multicentre study. JAMA 1993;270:2957-6314.
15. Vincent J-L, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-10.
16. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.
18. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Intensive Care Med 2013;39:165-228.
19. Giamarellou H, Poulakou G. Multidrug-resistant Gramnegative infections: what are the treatment options? Drugs 2009;69:1879-901.
20. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 2009;10:13-21.
21. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012;25:682-707.
22. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6.
23. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94.
24. Korth-Bradley JM, Troy SM, Matschke K, Muralidharan G, Fruncillo RJ, Speth JL et al. Tigecycline pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol 2012;52:1379-87.
25. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013;57:1756-62.
26. Psichogiou M, Tassios PT, Avlamis A, Stefanou I, Kosmidis C, Platsouka E et al. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 2008;61:59-63.
27. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010;50:364-73.
28. Corona A, Bertolini G, Lipman J, Wilson AP, Singer M. Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010;65:1276-85.
29. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009;47:1611-12.
30. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007;59:786-90.
31. Baptista JP, Neves M, Rodrigues L, Teixeira L, Pinho J, Pimentel J. Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients. J Nephrol 2014 [In press].
32. Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations∗. Crit Care Med 2014;42:520-7.